While keeping it brief, one key point is that for many patients with comorbidities like cardiovascular disease, the safety profile of established PDE5 inhibitors still reigns supreme—especially given their extensive long-term data. That said, newer agents with potentially faster onset or different metabolic pathways might be game-changers for patients who don’t respond well to the classics, but they’re still playing catch-up in real-world scenarios and long-term safety. It’s definitely worth watching how adjunct therapies perhaps synergize with these drugs, but as always, individual risk factors remain the bottom line when tailoring treatment.